NYSE:BMYPharmaceuticals
Bristol Myers Squibb Oncology Deal With Oxford BioTherapeutics Tests Valuation
Bristol Myers Squibb (NYSE:BMY) announced a multi year collaboration with Oxford BioTherapeutics to develop next generation T cell engager therapies for solid tumors.
The partnership combines Oxford BioTherapeutics' target discovery platform with Bristol Myers Squibb's oncology expertise to expand its immuno oncology pipeline.
The agreement focuses on solid tumor treatments and is intended to broaden Bristol Myers Squibb's late stage research portfolio and potential revenue sources.
Bristol...